Axsome Therapeutics (AXSM) Assets Average (2016 - 2026)

Axsome Therapeutics (AXSM) has 11 years of Assets Average data on file, last reported at $701.7 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 20.45% year-over-year to $701.7 million; the trailing twelve-month figure through Mar 2026 stood at $701.7 million (up 20.45% YoY), and the FY2025 full-year result was $629.2 million, up 8.78% from the prior year.
• Assets Average climbed to $701.7 million in Q1 2026, from $679.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $701.7 million in Q1 2026 to a low of $88.2 million in Q1 2022.
• A 5-year average of $491.2 million and a median of $565.0 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average plunged 50.05% in 2022 and jumped 308.66% in 2023, its largest moves.
• Tracing AXSM's Assets Average over 5 years: stood at $335.2 million in 2022, then jumped by 77.36% to $594.5 million in 2023, then dropped by 4.97% to $565.0 million in 2024, then gained by 20.28% to $679.5 million in 2025, then increased by 3.26% to $701.7 million in 2026.
• Business Quant data shows AXSM's Assets Average at $701.7 million in Q1 2026, $679.5 million in Q4 2025, and $654.5 million in Q3 2025.